



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#53164

**Date:** September 11, 2023

**Subject:** Magenta Therapeutics, Inc. - Reverse Split and Name/Symbol/CUSIP Change  
Option Symbol: MGTA  
New Symbol: DNTH1  
Date: 09/12/2023

Magenta Therapeutics, Inc. (MGTA) has announced a 1-for-16 reverse stock split, and name, symbol, and CUSIP change in conjunction with a business combination with Dianthus Therapeutics, Inc. As a result, each MGTA Common Share will be converted into the right to receive 0.0625 (New) Dianthus Therapeutics, Inc. (DNTH) Common Shares. The reverse stock split and underlying changes will become effective before the market open on September 12, 2023. Cash will be paid in lieu of fractional shares resulting from the Reverse Split.

Additionally, under a CVR agreement, MGTA shareholders of record immediately prior to the effective time of the merger will receive one non-transferable Contingent Value Right (CVR) per share. The CVR represents a non-transferable contractual right to receive payments upon the occurrence of certain events as described in the Proxy Statement dated August 1, 2023.

**MGTA options will not be adjusted to call for the delivery of the CVRs.**

**Contract Adjustment**

**Effective Date:** September 12, 2023

**Option Symbol:** MGTA changes to DNTH1

**Contract Multiplier:** 1

**Strike Divisor:** 1

**New Multiplier:** 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

**New Deliverable Per Contract:**  
1) 6 (New) Dianthus Therapeutics, Inc. (DNTH) Common Shares  
2) Cash in lieu of 0.25 fractional DNTH Shares

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

**CUSIP:** DNTN (New): 252828108

### **Pricing**

Until the cash in lieu amount is determined, the underlying price for DNTN1 will be determined as follows:

$$\text{DNTN1} = 0.0625 (\text{DNTN})$$

### **Delayed Settlement**

The DNTN component of the DNTN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the DNTN1 deliverable until the cash in lieu of fractional DNTN Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).